All-cause Mortality Cox Proportional Hazards Model1

Study Endpoints   >   Primary   >   All Cause Mortality
  • Tafamidis was associated with 30%† reduction in the risk of all-cause mortality compared with placebo (29.5% vs 42.9%)
  • HR=0.70 (95% CI, 0.51-0.96; p=0.0259)
  • This analysis was not adjusted for multiplicity
Probability of Survival
Months Since First Dose
Pooled tafamidis
Placebo
Hazard ratio, 0.70 (95% CI, 0.51- 0.96)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0
3
6
9
12
15
18
21
24
27
30
33

Number needed to treat (NNT): 7.5*
~8 patients would need to be treated
to prevent 1 death within 30 months*.

No. at Risk (cumulative no. of events)

Pooled tafamidis 264 (0) 259 (5) 252 (12) 244 (20) 235 (29) 222 (42) 216 (48) 209 (55) 200 (64) 193 (71) 99 (78) 0 (78)
Placebo 177 (0) 173 (4) 171 (6) 163 (14) 161 (16) 150 (27) 141 (36) 131 (46) 118 (59) 113 (64) 51 (75) 0 (76)

*Data on file. Pfizer Inc, New York, NY.
†Heart transplant and implantation of a cardiac mechanical assist device implantation were treated as death for this analysis.

CI: confidence interval; HR: hazard ratio.